Neuromuscular abnormalities in critical illness;Patología neuromuscular en cuidados intensivos

Medicina Intensiva

Volumn 33, Issue 3, 2009, Pages 123-133

  Amaya Villar, R ^a   Garnacho Montero, J ^a   Rincon Ferrari M D ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Critical illness; Muscle weakness; Pathophysiology; Prognosis; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; PYRIDOSTIGMINE;

ARTICLE; CRITICAL ILLNESS; CRITICAL ILLNESS POLYNEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; PATHOPHYSIOLOGY; PLASMAPHERESIS; POLYNEUROPATHY; PROGNOSIS;

CLINICAL PROTOCOLS; CRITICAL ILLNESS; GUILLAIN-BARRE SYNDROME; HUMANS; INTENSIVE CARE UNITS; MUSCULAR DISEASES; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASES; POLYNEUROPATHIES; PROGNOSIS;

EID: 65549145165     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(09)70945-3     Document Type: Article

References (70)

1. Mehta S. Neuromuscular disease causing acute respiratory failure. Respir Care 51 (2006) 1016-1021
2. Van der Meché F.G., Van Doorn P.A., Meulstee J., and Jennekens F.G. GBS-consensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 45 (2001) 133-139
3. Hughes R.A., and Cornblath D.R. Guillain-Barré Syndrome. Lancet 366 (2005) 1653-1666
4. Guillain-Barré Syndrome Study Group. Guillain-Barré Syndrome: an Italian multicentre case-control study. Neurol Sci 21 (2000) 229-234
5. Kiefer R., Kieseier B.C., and Hartung H.P. Immune-mediated neuropathies. In: Pourmand R., and Harati Y. (Eds). Neuromuscular disorders (2001), Lippincott Williams & Wilkins, Philadelphia 111-131
6. Hughes R.A., Wijdicks E.F., Benson E., Cornblath D.R., Hahn A.F., Meythaler J.M., et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 62 (2005) 1194-1198
7. Freeman R. Autonomic peripheral neuropathy. Neurol Clin 25 (2007) 277-301
8. Taguchi Y., Takashima S., and Sasahara E. Inappropriate secretion of antidiuretic hormone in a patient with chronic inflammatory demyelinating polyneuropathy. Intern Med 44 (2005) 65-67
9. Papazian O., and Alfonso I. Polirradiculoneuropatías autoinmunes agudas. Rev Neurol 34 (2002) 169-177
10. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35 (1985) 1096-1104
11. Mc Khann G.M., Griffin J.W., Cornblath, Mellits E.D., Fisher R.S., and Quaskey S.A. Plasmapheresis and the Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23 (1988) 347-353
12. The French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Appopriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 41 (1997) 298-306
13. Hughes R.A., Swan A.V., Raphaël J.C., Annane D., Van Koningsveld R., and Van Doorn P.A. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130 (2007) 2245-2257
14. Van der Meché F.G.A., Schmitz P.I.M., and Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 326 (1992) 1123-1129
15. Hughes R.A., Raphael J.C., Swan A.V., and Van Doorn P.A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2 (2001) CD002063
16. Plasma Exchange/Sandoglobulin Guillain-Barré Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatmets in Guillain-Barré syndrome. Lancet 349 (1997) 225-230
17. Guillain-Barré Syndrome Steroid Trial Group. Double-blind study of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341 (1993) 586-590
18. Wollinsky K.H., Hülser P.J., Brinkmeier H., Aulkemeyer P., Bössenecker W., Huber-Hartmann K.H., et al. CSF filtration is an effective treatmen of Guillain-Barré syndrome. A randomized clinical trial. Neurology 57 (2001) 774-780
19. Koningsveld R.V., Steyerberg E.W., Hughes R.A., Swan A.V., Van Doorn P.A., and Jacobs B.C. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 6 (2007) 589-594
20. Visser L.H., Schmitz P.I.M., Meulstee J., Van Doorn P.A., and Van der Meché F.G.A. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Neurology 53 (1999) 598-604
21. De la Cour C.D., and Jakobsen J. Residual neuropathy in longterm population-based follow-up of Guillain-Barré syndrome. Neurology 64 (2005) 246-253
22. Drachman D.B. Myasthenia gravis. N Engl J Med 330 (1994) 1797-1802
23. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 116 (2006) 2843-2854
24. Scherer K., Bedlack R., and Simel D. Does this patient have myasthenia gravis?. JAMA 293 (2005) 1906-1914
25. Jani-Acsadi A., and Lisak R. Myasthenic crisis: Guidelines for prevention and treatment. J Neurol Sci 261 (2007) 127-133
26. Schneider-Gold C., Gajdos P., Toyka K.V., and Hohlfeld R.R. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2 (2005) CD002828
27. Berrouschot J., Baumann I., Kalischewski P., Sterker M., and Schneider D. Therapy of myasthenic crisis. Crit Care Med 25 (1997) 1228-1235
28. Gajdos P., Chevret S., Clair B., Tranchant C., and Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41 (1997) 789-796
29. Hart I.K., Sathasivam S., and Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 4 (2007) CD005224
30. Calhoun R., Ritter J.H., Guthrie T.J., Pestronk A., Meyers B.F., Patterson G.A., et al. Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients. Ann Surg 230 (1999) 555-561
31. Bolton C.F., Gilbert J.J., Hahn A.F., and Sibbald W.J. Polyneuropathy in critically ill patient. J Neurol Neurosurg Psych 47 (1984) 1223-1231
32. Latronico N., Fenzi F., Recupero D., Guarneri B., Tomelleri G., Tonin P., et al. Critical illness myopathy and neuropathy. Lancet 347 (1996) 1579-1582
33. Schweickert W.D., and Hall J. ICU-acquired weakness. Chest 13 (2007) 1154-1159
34. Stevens R., Dowdy D., Michaels R., Mendez-Tellez P., Pronovost P., and Needham D. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 33 (2007) 1876-1891
35. Witt N.J., Zochodne D.W., Bolton C.F., Maison F.G., Wells G., Young B., et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 99 (1991) 176-184
36. Garnacho-Montero J., Madrazo-Osuna J., García Garmendia J.L., Ortiz Leyba C., Jiménez-Jiménez F.J., Barrero-Almodóvar A.E., et al. Critical illness polyneuropathy: Risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 27 (2001) 1288-1296
37. De Letter M.A., Schmitz P.I., Visser L.H., Verheul F.A.M., Schellens R.L.L.A., Op de Coul D.A.W., et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 29 (2001) 2281-2286
38. Druschky A., Herkert M., Radespiel-Tröger M., Druschky K., Hund E., Becker C.M., et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 27 (2001) 686-693
39. De Jonghe B., Sharshar T., Lefaucheur J.P., Authier F.J., Durand-Zaleski I., Boussarsar M., et al. Paresis acquired in the intensive care unit. A prospective multicenter study. JAMA 288 (2002) 2859-2867
40. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
41. Van den Berghe G., Wouters P.J., Bouillon R., Weekers F., Verwaest C., Schetz M., et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31 (2003) 359-366
42. Hermans G., Wilmer A., Masserman W., Milants I., Weuters P.J., Bobbaers H., et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 175 (2007) 480-489
43. Bolton C. Neuromuscular manifestations of critical illness. Muscle Nerve 32 (2005) 140-163
44. Mesejo A., Pérez-Sancho E., and Moreno E. Clinical consequences of neuromuscular impairments in critically ill patients. Nutr Hosp 21 (2006) 104-113
45. Bolton C.F. Electrophysiologic studies of critically ill patients. Muscle Nerve 10 (1987) 129-135
46. Khan J., Harrison T.B., Rich M.M., and Moss M. Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 67 (2006) 1421-1425
47. Hund E., Genzwurker H., Böhrer H., Jakob H., Thiele R., and Hacke W. Predominant involvement of the motor fibres in patients with critical illness polyneuropathy. Br J Anaesthesia 78 (1997) 274-279
48. Coakley J.H., Nagendran K., Yarwood G.D., Honavar M., and Hinds C.J. Patterns of neurophysiological abnormalities in prolonged critical illness. Intensive Care Med 24 (1998) 801-807
49. De Seze M., Petit H., Wiart L., Cardinaud J.P., Gaujard E., Joseph P.A., et al. Critical illness polyneuropathy. A 2-year followup study in 19 severe cases. Eur Neurol 43 (2000) 61-69
50. Herridge M.S., Chenung A.M., Tansey C.M., Matte-Martyn A., Díaz-Granados N., Al-Saidi F., et al. One-year outcomes in survivors of acute respiratory distress syndrome. N Engl J Med 348 (2003) 683-693
51. Fletcher S.N., Kennedy D.D., Ghosh I.R., Misra V.P., Kiff K., Coakley J.H., et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 31 (2003) 1012-1106
52. Leijten F.S.S., Harinck-De Weerd J.E., Poortvliet D.C., and De Weerd A.W. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 274 (1995) 1221-1225
53. Leijten F.S.S., De Weerd A.W., Poortvliet D.C., De Ridder V.A., Ulrich C., and Harinck-De Weerd J.E. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 22 (1996) 856-861
54. De Jonghe B., Bastuji-Garin S., Sharshar T., Outin H., and Brochard L. Does ICU-acquired paresis lengthen weaning from mechanical ventilation?. Intensive Care Med 30 (2004) 1117-1121
55. Garnacho-Montero J., Amaya-Villar R., García-Garmendía J.L., Madrazo-Osuna J., and Ortiz-Leyba C. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 33 (2005) 349-354
56. Garnacho-Montero J., Amaya-Villar R., and Ortiz-Leyba C. Critical illness polyneuropathy. Crit Care Med 33 (2005) 1675
57. De Jonghe B., Bastuji-Garin S., Durand M.C., Malissin I., Rodrigues P., Cerf C., et al. Respiratory weakness is associated with limb weakness and delayed weaning in critical illness. Crit Care Med 35 (2007) 2007-2015
58. MacFarlane I.A., and Rosenthal F.D. Severe myopathy after status asthmaticus. Lancet 2 (1977) 615
59. Hund E. Myopathy in critically ill patients. Crit Care Med 27 (1999) 2544-2547
60. Lacomis D., Petrella J.T., and Giuliani M.J. Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients. Muscle Nerve 21 (1998) 610-617
61. Helliwell T.R., Coakley J.H., Wagemakers A.J., Griffiths R.D., Campbell I.T., Green C.J., et al. Necrotizing myopathy in critical ill patients. J Pathol 164 (1991) 307-314
62. Behbehani N.A., Al-Mane F., D'yachkova Y., Pare P., and FitzGerald J.M. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids. Chest 115 (1999) 1627-1631
63. Amaya-Villar R., Garnacho-Montero J., García-Garmendía J.L., Madrazo-Osuna J., Garnacho-Montero M.C., Luque R., et al. Myopathy in patients intubated for exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 31 (2005) 157-161
64. Tiao G., Hobler S., Wang J.J., Meyer T.A., Luchette F.A., Fischer J.E., et al. Sepsis is associated with increased mRNAs of ubiquitinproteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99 (1997) 163-168
65. Showalter C.J., and Engel A.G. Acute quadriplegic myopathy: Analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 20 (1997) 316-322
66. Tsukagoshi H., Morita T., Takahashi K., Kunimoto F., and Goto F. Cecal ligation and puncture peritonitis model shows a decrease nicotinic acetylcholine receptor numbers in rat muscle: Immunopathologic mechanisms?. Anesthesiology 91 (1999) 448-460
67. Bazzi P., Moggio M., Prelle A., Sciacco M., Messina S., Barberini S., et al. Critically ill patients: immunological evidence of inflammation in muscle biopsy. Clin Neuropath 18 (1999) 23-30
68. Leatherman J.W., Fluegel W.L., David W.S., Davies S.F., and Iber C. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 153 (1996) 1686-1690
69. Adnet F., Dhissi G., Borron S.W., Galinski M., Rayeh F., Cupa M., et al. Complication profiles of adult asthmatics requiring paralysis during mechanical ventilation. Intensive Care Med 27 (2001) 1729-1736
70. Campellone J.V., Lacomis D., Kramer D.J., Van Cott A.C., and Giuliani M.J. Acute myopathy after liver transplantation. Neurology 50 (1998) 46-53